Journal publications

Export 68 results:
Author Title Type [ Year(Asc)]
Filters: Type is Journal Article  [Clear All Filters]
2010
UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study(UK CHIC).  2010.  Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis. 50:1275-85.
Mackie NE, Phillips A, Kaye S, Booth C, Geretti A M.  2010.  Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 201:1303-7.
Harrison LJ, Castro H, Cane P A, Pillay D, Booth C, Phillips A, Geretti A M, Dunn D.  2010.  The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS. 24:1917-22.
Dunn D, von Wyl V., Price H., Asboe D.  2010.  The impact of the 0-0 cell on measures of amino acid covariation. AIDS. 24:159-60.
Bansi L, Geretti A M, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips A et al..  2010.  Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr. 53:633-9.
Price H., Asboe D, Pozniak A, Gazzard B, Fearnhill E, Pillay D, Dunn D.  2010.  Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data. Antivir Ther. 15:203-11.
de Oliveira T, Pillay D, Gifford RJM.  2010.  The HIV-1 subtype C epidemic in South America is linked to the United Kingdom. PLoS One. 5:e9311.
Chilton DN, Castro H, Lattimore S, Harrison LJ, Fearnhill E, Delpech V, Rice B., Pillay D, Dunn D.  2010.  HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Antivir Ther. 15:985-91.
2009
Hughes GJ, Fearnhill E, Dunn D, Lycett SJ, Rambaut A, Leigh Brown A.J.  2009.  Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom. PLoS Pathog. 5:e1000590.
Harrison LJ, Dunn D, Green H, Copas A.  2009.  Modelling the association between patient characteristics and the change over time in a disease measure using observational cohort data. Stat Med. 28:3260-75.
Pond S.LKosakov, Posada D., Stawiski E., Chappey C., Poon A.F, Hughes GJ, Fearnhill E, Gravenor M.B, Leigh Brown A.J, Frost S.D.  2009.  An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. PLoS Comput Biol. 5:e1000581.
Geretti A M, Harrison LJ, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D.  2009.  Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis. 48:1296-305.
Hué S, Gifford RJM, Dunn D, Fernhill E, Pillay D.  2009.  Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol. 83:2645-54.
Gupta R.K, Hill A., Sawyer A.W, Cozzi-Lepri A, von Wyl V., Yerly S., Lima V.D, Gunthard H.F, Gilks C., Pillay D.  2009.  Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 9:409-17.
2008
Green H, Tilston P, Fearnhill E, Pillay D, Dunn D.  2008.  The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr. 49:196-204.
Chakraborty R., Smith CJ, Dunn D, Green H, Duong T., Doerholt K., Riordon A., Lyall H., Tookey P, Butler K. et al..  2008.  HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J. 27:457-9.
Grover D, Copas A, Green H, Edwards SG, Dunn D, Sabin C, Phillips A, Allen E., Pillay D.  2008.  What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? J Antimicrob Chemother. 61:705-13.
Cozzi-Lepri A.  2008.  Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response. HIV Med. 9:27-40.
Assoumou L., Brun-Vezinet F., Cozzi-Lepri A, Kuritzkes D., Phillips A, Zolopa A., Degruttola V., Miller V., Costagliola D..  2008.  Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. J Infect Dis. 198:470-80.
Dunn D, Geretti A M, Green H, Fearnhill E, Pozniak A, Churchill D, Pillay D, Sabin C, Phillips A.  2008.  Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. Antivir Ther. 13:771-7.